Colorectal Cancer (Locally Advanced or Metastatic) clinical trials

CDH17 car-t therapy for advanced solid tumors

This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.

Tattoo marking breast tumors before chemo

This trial tests a simple method: marking the tumor with a small tattoo before chemotherapy. The tattoo helps surgeons find the exact spot for lumpectomy after the tumor shrinks, so you can keep more of your breast.

Testing ZI-MA4-1 immunotherapy for advanced solid cancers

This early-stage trial tests a new type of immunotherapy called ZI-MA4-1 in patients with advanced cancers (ovarian, lung, synovial sarcoma, or head and neck) that have stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells that have a specific protein called MAGE-A4.

Imaging small live tumor details during surgery

This study uses a special camera to look at solid tumors from inside the body during an operation. It tests whether “live” tumor imaging (using a medicine called fluorescein) can be safely performed in people with certain solid cancers.

Study of OP-3136 for advanced solid tumors

This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.

Pump-delivered therapy plus chemo for liver-metastatic cancers

This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.

MRI scan to track response in colorectal liver metastases

This study uses a special MRI scan to see how colorectal cancer in the liver responds to planned chemotherapy before and after surgery. It may help doctors better measure treatment success and plan care.

Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems

This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Glowing dye to help surgeons see lung cancer during surgery

This trial tests a dye that makes lung cancer cells glow during surgery, helping surgeons remove more of the tumor. It's for people who are already scheduled for lung cancer surgery.

Continuing opnurasib treatment for patients who are benefiting

This trial allows people who are already taking opnurasib in another Novartis study and seeing good results to keep receiving it. The goal is to let them continue treatment without interruption.

Mobile app coaching for planning care after serious cancer

This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).

Is a new immunotherapy better than Keytruda for squamous lung cancer?

This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.

Study of GDC-4198 alone or with giredestrant for advanced breast cancer

This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.

Comparing a new drug to chemo for advanced bladder cancer

This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.

New drug combo for advanced bladder cancer

This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.

Testing BAY 3771249 for Advanced Colorectal Cancer With KRAS Mutation

This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.

Testing SKB571 for MET-mutated advanced lung cancer

This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.

Surufatinib before surgery for advanced thyroid cancer

This trial tests whether the drug Surufatinib, given before surgery, can shrink locally advanced or metastatic thyroid cancer. It's a targeted therapy that blocks blood vessels that feed tumors, and is given as a pill to see if it makes the cancer easier to remove.

Targeted drug for HER2-positive castration-resistant prostate cancer

This trial tests a new drug called Disitamab Vedotin for men with advanced prostate cancer that is no longer responding to hormone therapy. The drug targets a protein called HER2 on cancer cells to try to shrink or slow the cancer.

HLX22 plus Enhertu for HR+, HER2-low breast cancer

This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.

Study of Ivonescimab with TAS-102 for advanced colorectal cancer

This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.

Study of RO7771950 vs tucatinib for HER2-positive breast cancer

This trial tests a new drug, RO7771950, against another drug called tucatinib. Both are given with standard chemotherapy to see which works better for advanced breast cancer that is HER2-positive. People with brain metastases may join.

Combination therapy for advanced gallbladder cancer

This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.